Advanced Polymer Coatings (APC) Collaborates with Albert Invent to Scale the Future of Modern R&D Infrastructure for Coatings
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myel
Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progr
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
WilliamsMarston's AIT Consulting Services Wins OneStream AI Excellence Award
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMON
Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patie
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
OneStream Unveils Forward Finance Blueprint to Help CFOs Lead Enterprise AI and Future-Proof the Business
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer
These 3 Companies Crushed Key Metrics This Earnings Season
OneStream, Inc. $OS Shares Bought by JPMorgan Chase & Co.
Capricorn Fund Managers Ltd Buys New Position in OneStream, Inc. $OS
OneStream Announces Completion of Acquisition by Hg for $6.4 Billion
OneStream Named a 4x Leader and Placed Furthest in Vision in the 2026 Gartner Magic Quadrant for Financial Close and Consolidation Solutions
OneStream Announces Splash 2026 and the OneStream World Tour to Help Finance Lead in a Time of Rapid Change
OneStream, Inc. $OS Shares Sold by Quantbot Technologies LP
ONESTREAM ANALYSIS: Is $24.00 Per Share a Fair Stockholder Buyout Offer? Kaskela Law Firm Announces Investigation into Fairness of Buyout Offer and Encourages Investors to Contact the Firm - OS
Kaskela Law Firm Announces Investigation into Fairness of Impending OneStream, Inc. (NASDAQ: OS) Shareholder Buyout and Encourages Current OS Shareholders to Contact the Firm
KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Onestream (OS) Reports Q4 Earnings: What Key Metrics Have to Say
Onestream (OS) Tops Q4 Earnings and Revenue Estimates
OneStream Announces Fourth Quarter and Fiscal Year 2025 Financial Results
ONESTREAM SHAREHOLDER NOTE: Kaskela Law Firm Announces Investigation of OneStream, Inc. Shareholder Buyout Proposal and Encourages Investors to Contact the Firm – OS
Counterpoint Mutual Funds LLC Acquires New Stake in OneStream, Inc. $OS
Countdown to Onestream (OS) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
SHAREHOLDER ALERT: Kaskela Law Firm Announces Active Investigation into OneStream, Inc. Shareholder Buyout and Encourages Investors to Contact the Firm - OS
Kaskela Law Firm Announces Investigation into Fairness of OneStream, Inc. (NASDAQ: OS) Shareholder Buyout and Encourages Current OS Shareholders to Contact the Firm
Onestream (OS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Will Onestream (OS) Beat Estimates Again in Its Next Earnings Report?
OneStream Named a Leader in the IDC MarketScape for Enterprise Planning, Budgeting, and Forecasting Applications Vendor Assessment
OneStream's Chief Revenue Officer Exercises Over 100k Shares as Share Prices Soar In January
OneStream Announces Timing of its Fourth Quarter and Full-Year 2025 Financial Results
Johnson Fistel Investigates OneStream, Inc. (OS) Shareholders' Rights Following Board Approval of $24.00 Take-Private Transaction
OneStream, Inc. (NASDAQ:OS) Given Consensus Rating of “Hold” by Brokerages
Johnson Fistel Investigates OneStream, Inc. (OS) Shareholders' Rights Following Board Approval of $24.00 Take-Private Transaction
Berman Tabacco Announces Investigation of OneStream, Inc. (NASDAQ:OS)
What Investors Should Know About a $186K OneStream Insider Stock Sale
Pamela Mcintyre Sells 6,505 Shares of OneStream (NASDAQ:OS) Stock
OneStream (NASDAQ:OS) vs. Match Group (NASDAQ:MTCH) Head-To-Head Analysis